Related Experiment Video
Updated: Jun 1, 2026
06:51
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.
Brandon Blue1, Paige Lake2, Joseph Pidala3
1Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.
Summary
Oncologists show moderate confidence in CAR T-cell therapy but need more education and patient materials. Improving these areas may enhance physician confidence and referral patterns for leukemia and lymphoma treatments.
Area of Science:
- Oncology
- Hematology
- Immunotherapy
Background:
- Chimeric antigen receptor T-cell (CAR T) therapy offers a promising treatment for leukemia and lymphoma.
- Understanding oncologists' perspectives on CAR T therapy is crucial for its effective implementation.
Purpose of the Study:
- To assess Florida oncologists' attitudes, knowledge, and referral patterns regarding CAR T therapy.
- To identify gaps in understanding and practice for CAR T in specific B-cell malignancies and leukemia.
Main Methods:
- A survey was distributed to 771 Florida oncologists and hematologists.
- 67 completed surveys (10% response rate) were analyzed using descriptive statistics.
Main Results:
- Physicians reported moderate confidence (49.2%-60%) in CAR T efficacy, toxicity, and indications.
- Most physicians discussed CAR T with patients, who expressed concerns about safety (31.7%) and cost (39.7%).
- Educational materials for patients are rarely available (73% never/rarely).
Conclusions:
- Community oncologists require further education on CAR T therapy.
- Developing patient educational materials is essential to support decision-making and improve physician confidence and referral rates.
